When interpreting these results, it is critical to consider that pharmacokinetic variability of MMF is influenced by differences in albumin, bilirubin, and hemoglobin concentrations; renal and hepatic function; enterohepatic recirculation; co-administration of CsA; comorbidities such as cystic fibrosis; body weight; concomitant medications; time post-transplantation; gender; race; and genetic polymorphisms in drug-metabolizing enzymes. The gene discussed is ALB; the disease is cystic fibrosis.